Yes , it certainly elevated PAA into the fray,, ODD is closely...

Yes , it certainly elevated PAA into the fray,, ODD is closely monitored by Big Pharma , imagine 10,000 Potential Drugs in Discovery mode , 9000 are culled as the Science doesn't stack up , 1000 then begin Phase I Trials , only 100 pass Safety and Tolerability some with average scores ,,very average scores , 10 continue with efficacy and Patient benefits and then only 1 of them is awarded FDA ODD.... well that's MPL ..

Big Pharma only then need to monitor the FDA ODD applications and then have laser focus on the absolute few that are granted FDA ODD...

ODD comes with some seriously significant benefits ...

7 Years market Exclusivity ,,, this pulls the ladder up behind us ,, not only wont we have any competition in the mTOR Pathway space for the Treatment of MND ,, BP with all their might cant compete with us ,, so yes with the 3 policies of BP "Meet , Greet and Eat" I think with approved FDA ODD we are on the Menu..and we are a main not an appetizer.. and the Menu was just edited with two other mains heading for the bin...NZT